The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors-Reference-Cited by-同舟云学术

The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors

Published:2015-10-02 Issue:34 Volume:6 Page:36731-36745
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bollard Julien¹,Massoma Patrick¹,Vercherat Cécile¹,Blanc Martine¹,Lepinasse Florian²,Gadot Nicolas³,Couderc Christophe¹,Poncet Gilles⁴,Walter Thomas⁴,Joly Marie-Odile¹²⁵,Hervieu Valérie¹²⁵,Scoazec Jean-Yves¹²³⁵,Roche Colette¹

Affiliation:

1. Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286, Equipe «Différenciation endocrine et tumorigenèse», Faculté Laënnec, F-69372 Lyon, France

2. Hospices Civils de Lyon, Hôpital Edouard Herriot, Service Central d'Anatomie et de Cytologie Pathologiques, F-69437 Lyon, France

3. Université Lyon 1, Fédération de Recherche Santé Lyon-Est, ANIPATH, Faculté Laennec, F-69372 Lyon, France

4. Hospices Civils de Lyon, Hôpital Edouard Herriot, Fédération des Spécialités Digestives, F-69437 Lyon, France

5. Université de Lyon, Université Lyon 1, F-69622 Villeurbanne, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms;Endocrine-Related Cancer;2024-04-16

2. Small Intestinal, Colorectal, and Appendicular Neuroendocrine Tumors;Neuroendocrine Tumours;2024

3. Semaphorin 3F induces colorectal cancer cell chemosensitivity by promoting P27 nuclear export;Frontiers in Oncology;2022-09-02

4. Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-09

5. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications;Frontiers in Oncology;2022-08-17